文献速递临床试验与 GCP

低剂量替格瑞洛联合阿司匹林预防高危非致残性缺血性脑血管事件早期神经功能恶化:一项PROBE临床研究

Low-dose ticagrelor combined with aspirin in the prevention of early neurological deterioration of high-risk non-disabling ischemic cerebrovascular events: a PROBE clinical study.
PubMed 文献 · Trials · 2026-04-06

本研究为多中心、前瞻性、随机、开放标签、盲法终点(PROBE)临床试验,计划纳入240例未接受再灌注治疗的高危非致残性缺血性脑血管事件(HR-NICE)患者,随机分为替格瑞洛(首日120mg,次日起60mg每日两次)联合阿司匹林(100mg/日)组与氯吡格雷(首日300mg,次日起75mg/日)联合阿司匹林(100mg/日)组,21天后均改为阿司匹林100mg/日单药。主要疗效终点为7天内早期神经功能恶化(END),安全性终点包括任何出血事件和死亡。该非劣效性试验旨在探讨低剂量替格瑞洛联合阿司匹林是否优于氯吡格雷联合阿司匹林预防HR-NICE患者END。

要点

  • 低剂量替格瑞洛联合阿司匹林可能为HR-NICE患者预防END提供新选择。
  • 主要疗效终点为7天内END,安全性关注任何出血事件和死亡。
  • 21天后统一改为阿司匹林100mg/日单药治疗。

核心结论

  • 该非劣效性试验将探讨低剂量替格瑞洛联合阿司匹林是否优于氯吡格雷联合阿司匹林预防HR-NICE患者END。

研究设计与样本

  • 多中心、前瞻性、随机、开放标签、盲法终点(PROBE)临床研究,计划纳入240例未接受再灌注治疗的HR-NICE患者进行区组随机化。

关键数值与推荐

  • 替格瑞洛联合阿司匹林组(120例):首日口服替格瑞洛120mg和阿司匹林100mg,次日起替格瑞洛60mg每日两次口服、阿司匹林100mg每日一次口服。
  • 氯吡格雷联合阿司匹林组(120例):首日口服氯吡格雷300mg和阿司匹林100mg,次日起氯吡格雷75mg和阿司匹林100mg口服。
  • 21天后所有患者改为阿司匹林100mg每日一次口服。
  • 主要疗效终点为7天内早期神经功能恶化(END)。
  • 安全性终点包括任何出血事件和死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early neurological deterioration (END) seriously endangers the clinical prognosis of high-risk non-disabling cerebrovascular events (HR-NICE), and strong antiplatelet therapy is an effective means of preventing the occurrence of END. Studies have confirmed that ticagrelor can avoid the low efficacy of clopidogrel in antiplatelet therapy caused by CYP2C19 gene dysfunction and that its combination with aspirin can improve the clinical prognosis of patients with HR-NICE. However, the overall risk of bleeding events is relatively high. In this protocol, we compared the prevention and safety of END in patients with HR-NICE using aspirin combined with low-dose ticagrelor and aspirin combined with clopidogrel. METHODS AND ANALYSIS: This multicenter, prospective, randomised, open-label, blinded endpoints (PROBE) clinical study intended to enrol 240 patients with HR-NICE who have not undergone reperfusion therapy for block randomization. Ticagrelor combined with aspirin group (120 cases): the patients were given 120 mg of ticagrelor and 100 mg of aspirin orally on the first day of enrollment, and from the next day onwards, ticagrelor 60 mg twice daily orally and aspirin 100 mg daily orally. The clopidogrel combined with aspirin group (120 cases) was administered 300 mg clopidogrel and 100 mg aspirin orally on the first day of enrollment, and starting from the next day, 75 mg clopidogrel and 100 mg aspirin were administered orally. After 21 days, all patients were changed to aspirin 100 mg daily orally. The main efficacy outcome is the early neurological deterioration within 7 days. Safety outcomes include any bleeding events and death. DISCUSSION: This non-inferiority trial will explore whether low-dose ticagrelor combined with aspirin is superior to clopidogrel combined with aspirin for the prevention of END in patients with HR-NICE patients. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee of The First Affiliated Hospital of Dalian Medical University (Number Project ID PJ-KS-KY-2023-03(X)). The research results will be published as a journal article. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2300068509. Registered on February 21, 2023. https://www.chictr.org.cn/ .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Wang M, Chen R, Yu X, et al. Low-dose ticagrelor combined with aspirin in the prevention of early neurological deterioration of high-risk non-disabling ischemic cerebrovascular events: a PROBE clinical study. Trials. 2026. PMID: 41943054. doi:10.1186/s13063-026-09691-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。